DiamiR Biosciences and Aptorum Group Ltd. Secure New York State Approval for APOE Genotyping Test
Aptorum Group Ltd., in collaboration with DiamiR Biosciences, has announced the approval of DiamiR's APOE Genotyping test by the New York State Department of Health (NYSDOH) under the Clinical Laboratory Evaluation Program (CLEP). This approval allows DiamiR to offer its validated molecular testing across various biological samples, including blood and saliva, through its CLIA-certified, CAP-accredited laboratory. This regulatory milestone enables the expanded availability of a critical diagnostic tool for assessing brain health and risks related to neurodegenerative diseases, enhancing personalized care strategies and clinical trial enrollment.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptorum Group Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9516098-en) on August 21, 2025, and is solely responsible for the information contained therein.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。